Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 4
2001 1
2002 2
2003 2
2004 7
2005 2
2011 1
2012 2
2013 3
2014 2
2016 7
2017 5
2018 1
2020 1
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside.
Bray-French K, Hartman K, Steiner G, Marban-Doran C, Bessa J, Campbell N, Martin-Facklam M, Stubenrauch KG, Solier C, Singer T, Ducret A. Bray-French K, et al. Among authors: martin facklam m. J Pharm Sci. 2021 Jul;110(7):2575-2584. doi: 10.1016/j.xphs.2021.03.027. Epub 2021 Apr 1. J Pharm Sci. 2021. PMID: 33812888 Free article. Review.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
[Drug interactions with the cytochrome P-450 system].
Martin-Facklam M, Drewe J, Haefeli WE. Martin-Facklam M, et al. Dtsch Med Wochenschr. 2000 Jan 21;125(3):63-7. doi: 10.1055/s-2007-1023908. Dtsch Med Wochenschr. 2000. PMID: 10682001 Review. German. No abstract available.
Inhibition of P-glycoprotein by newer antidepressants.
Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Weiss J, et al. Among authors: martin facklam m. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. doi: 10.1124/jpet.102.046532. J Pharmacol Exp Ther. 2003. PMID: 12649369
High prevalence of unknown co-medication in hospitalised patients.
Rieger K, Scholer A, Arnet I, Peters FT, Maurer HH, Walter-Sack I, Haefeli WE, Martin-Facklam M. Rieger K, et al. Among authors: martin facklam m. Eur J Clin Pharmacol. 2004 Jul;60(5):363-8. doi: 10.1007/s00228-004-0784-6. Epub 2004 Jun 10. Eur J Clin Pharmacol. 2004. PMID: 15197522
38 results